Cargando…
Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer
Chemotherapy-resistant breast cancer displays aggressive clinical behavior, is poorly differentiated and is associated with the occurrence of epithelial-mesenchymal transition and the presence of cancer stem cells. The anthelmintic drug niclosamide has been shown to have numerous clinical applicatio...
Autores principales: | Liu, Junjun, Ding, Hanzhi, Quan, Hong, Han, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299033/ https://www.ncbi.nlm.nih.gov/pubmed/34386088 http://dx.doi.org/10.3892/ol.2021.12927 |
Ejemplares similares
-
The Testing of Anthelminthics
por: Maplestone, P. A.
Publicado: (1932) -
Niclosamide inhibits ovarian carcinoma growth by interrupting cellular bioenergetics
por: Shangguan, Fugen, et al.
Publicado: (2020) -
Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014) -
Are Anthelminthic Treatments of Captive Ruminants Necessary?
por: Lahat, Liron, et al.
Publicado: (2021) -
Human epidermal growth factor receptor 2 positive rates in invasive lobular breast carcinoma: The Singapore experience
por: Kee, Ga-Jing, et al.
Publicado: (2020)